Compounds for the treatment of CNS disorders

US8623901B2 · kind B2 · utility

Assignee

• Boehringer Ingelheim International GmbH · DE

Inventors

• Riccardo Giovannini · Verona, IT
• Cornelia Dorner-Ciossek · Ingelheim am Rhein, DE
• Christian Eickmeier · Mittelbiberach, DE
• Dennis Fiegen · Biberach an der Riß, DE
• Thomas Fox · Biberach, DE
• Klaus Fuchs · Ingelheim am Rhein, DE
• Niklas Heine · Eberhardzell, DE
• Holger Rosenbrock · Mittelbiberach, DE
• Gerhard Schaenzle · Biberach, DE

Key dates

• Filing date: Mar 30, 2010
• Grant date: Jan 7, 2014
• Expiry date: Mar 10, 2031

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to novel 1,6-disubstituted pyrazolopyrimidinones of formula (I),in which Hc is a tetrahydropyranyl-group and R1 is the group V−W−*, whereby V and W independently of each other may be an aryl group or an heteroaryl group, which independently of each other may optionally be substituted.According to one aspect of the invention the new compounds are for use as medicaments or for the manufacture of medicaments, in particular medicaments for the treatment of conditions concerning deficits in perception, concentration, learning or memory. The new compounds are also for the manufacture of medicaments and/or for use in the treatment of e.g. Alzheimer's disease, in particular for cognitive impairment associated with Alzheimer's disease.